SVB Leerink Equities Analysts Increase Earnings Estimates for HilleVax, Inc. (NASDAQ:HLVX)

HilleVax, Inc. (NASDAQ:HLVXGet Rating) – Investment analysts at SVB Leerink boosted their Q2 2023 earnings per share (EPS) estimates for shares of HilleVax in a research note issued on Monday, May 15th. SVB Leerink analyst D. Risinger now anticipates that the company will post earnings of ($0.88) per share for the quarter, up from their previous estimate of ($1.00). The consensus estimate for HilleVax’s current full-year earnings is ($4.63) per share. SVB Leerink also issued estimates for HilleVax’s Q3 2023 earnings at ($1.00) EPS, Q4 2023 earnings at ($1.31) EPS, FY2023 earnings at ($3.90) EPS, Q1 2024 earnings at ($1.09) EPS, Q2 2024 earnings at ($0.87) EPS, Q3 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($3.20) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($2.27) EPS and FY2027 earnings at ($1.19) EPS.

HilleVax (NASDAQ:HLVXGet Rating) last posted its earnings results on Friday, March 17th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.42.

HilleVax Price Performance

Shares of HLVX opened at $15.90 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 22.28 and a current ratio of 14.00. The stock has a 50 day simple moving average of $14.70 and a 200 day simple moving average of $16.17. HilleVax has a 52-week low of $7.90 and a 52-week high of $24.42. The firm has a market capitalization of $623.28 million and a PE ratio of -4.24.

Hedge Funds Weigh In On HilleVax

Several institutional investors and hedge funds have recently modified their holdings of HLVX. Russell Investments Group Ltd. acquired a new position in shares of HilleVax in the 1st quarter valued at approximately $26,000. UBS Group AG grew its position in shares of HilleVax by 9,300.0% in the 4th quarter. UBS Group AG now owns 1,692 shares of the company’s stock valued at $28,000 after purchasing an additional 1,674 shares during the period. Shell Asset Management Co. acquired a new position in shares of HilleVax in the 4th quarter valued at approximately $41,000. Tower Research Capital LLC TRC boosted its position in HilleVax by 57.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock worth $43,000 after acquiring an additional 943 shares during the last quarter. Finally, Gyon Technologies Capital Management LP acquired a new position in HilleVax during the 4th quarter worth approximately $53,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Company Profile

(Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Featured Stories

Earnings History and Estimates for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with's FREE daily email newsletter.